3 Takeaways From Aphria Inc’s (TSX:APHA) Q3 Results

Aphria Inc (TSX:APHA)(NYSE:APHA) disappointed investors with its latest quarterly results, but is the stock still a good buy?

Aphria (TSX:APHA)(NYSE:APHA) released its third-quarter results on Monday. The company’s revenues were up more than 600% in what was its first quarter with a full three months of recreational sales. However, with Aphria recording a loss of more than $108 million, investors were left unimpressed, as the stock dropped 14% on the day the results were announced.

It was a bit of a mixed bag of results for the company, but here are three things that stood out to me in Aphria’s latest quarterly results.

Costs to produce cannabis are rising

Aphria has long positioned itself as a low-cost producer. And yet, during this past quarter, it saw its costs continue to rise. In Q3, costs to produce dried cannabis per gram were $1.48, which is up 10% from Q2 when costs were just $1.34. And if we look at “all-in” costs per gram, that also rose from $2.60 in Q2 to $3.76 for an increase of 45%.

With rising per-gram costs, it’s no wonder that Aphria’s gross margins before fair-value adjustments were just 18%. That’s a very low margin, and if that continues it’s only going to get more difficult for Aphria to stay out of the red.

LATAM assets were significantly overvalued

Last year, we heard about short-sellers being critical of Aphria’s LATAM assets and that they were heavily overvalued. Well, on Monday, we got confirmation of just that as the company had write-downs of $50 million relating to those assets.

For investors, it’s troubling because it calls into question Aphria’s decision making and whether management is making good acquisitions or not. Certainly, in this case, it doesn’t look good and might have investors second-guessing Aphria next time the company makes a big acquisition or investment.

Company is still nowhere near breakeven

Even if we take out the $58 million that Aphria incurred in impairment charges this past quarter, it still wouldn’t be nearly enough to pull the company out of the red. There’s, unfortunately, no shortage of issues plaguing the company and preventing it from being profitable. Low margins, rising operating expenses, and losses from non-operating items are some of the areas that need to be addressed before investors can have any real expectation that Aphria will be profitable.

Bottom line

Aphria achieved strong sales growth but not much else in its latest quarter. And while sales growth has been enough for marijuana stocks thus far, investors made it clear that that isn’t the case anymore. Otherwise, we would have seen the stock jump on earnings rather than crash.

Investors are paying some big premiums to own marijuana stocks; without some more substance behind them, it’s only going to become more difficult to justify keeping the stocks. Aphria has typically lagged behind some of its bigger competitors in the industry, and while it’s been off to a great start to 2019, these results may bring the bears back out.

And with no permanent replacement yet for Vic Neufeld, there’s still a lot of risk and uncertainty surrounding the company today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »